A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy
Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effect of partial correction of anemia with
Darbepoetin alfa to a target of 11 g.dL (female) or 12 g/dL (male) on the reduction of
cardiovascular morbidity and total mortality.